Compare Crispr Therapeutics AG (CRSP) vs SoFi Technologies Inc (SOFI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs SoFi Technologies Inc — how do they compare? Crispr Therapeutics AG trades at $51.2 (market cap $4.88B), while SoFi Technologies Inc trades at $15.76 (market cap $20.16B). The key difference: SoFi Technologies Inc is far larger — about 4.1× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, SoFi Technologies Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and SoFi Technologies Inc for 60 Days on average.
| CRSP | SOFI | |
|---|---|---|
Market Cap | $4.88B | $20.16B |
Volume | 2,861,747 | 49,646,331 |
Sector | Health | Financials |
52-Week High | $74.92 | $32.21 |
52-Week Low | $44.34 | $15.15 |
Typical Hold Time | 77 Days | 60 Days |
Enterprise Value | $3.30B | $20.30B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
SOFI Technologies stock trades at $15.66, down 0.64% on the day, with a bearish technical signal from moving averages and oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results expected soon. Revenue has grown from $1.6B in 2022 to $3.6B in 2025, though net income margins have fluctuated. Analyst consensus is a Buy with a $21.58 price target, but technical indicators suggest near-term pressure.
The outlook for SOFI is mixed: strong fundamentals and growth potential are offset by technical weakness and competitive risks. Investment opportunity lies in its revenue trajectory and market position, but investors face risks from execution challenges and interest rate sensitivity. The stock's current valuation metrics indicate premium pricing relative to peers, requiring careful monitoring of upcoming earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About SoFi Technologies Inc
SoFi is a financial services company that was founded in 2011 and is currently based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020 the company also offers payment and account services for debit cards and digital banking.
Read more on SOFI →
